TOPLINE: Inotuzumab ozogamicin (IO), an anti‐CD22 antibody conjugated with calicheamicin, was well tolerated and demonstrated an overall response rate of 74% in adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) in a real-world study. METHODOLOGY: Researchers conducted a multicentre retrospective cohort study involving 73 adult patients (median age at IO initiation, 52.7 years) with […]
The post Inotuzumab Shows Promise for ALL in Real-World Study first appeared on News Health.
Author : News Health
Publish date : 2025-03-31 12:00:00
Copyright for syndicated content belongs to the linked Source.